(Related data drawing)
The funds raised in this round of financing are mainly used for capacity upgrading, product iterative updating, and accelerating domestic and overseas commercial expansion.
Recently, Guangzhou Ruipai Medical Instrument Co., Ltd. (hereinafter referred to as "Ruipai Medical") announced that it had completed the C round of financing, with a total amount of several hundred million yuan. This round of financing was led by Yuexiu Industrial Fund, followed by Stowe Capital, Guoju Venture Capital, Caixin Private Placement, etc. The funds raised in this round of financing are mainly used for capacity upgrading, product iterative updating, and accelerating domestic and overseas commercial expansion.
Founded in 2015, Ruipai Medical is a national high-tech enterprise focusing on the production, R&D and sales of disposable endoscopes. The products cover disposable endoscope, medical endoscope image processor, disposable therapeutic instrument under endoscope, etc. The host platform of Ruipai Medical is based on the independently developed IPS image processing system, integrating SHIE ultra clear image quality engine, IET image enhancement algorithm, spectral dyeing and EBI texture enhancement, AI-LD lesion recognition, detection and other AI auxiliary diagnostic methods, improving the resolution and clarity of image details while providing doctors with lesion reference. At present, Ruipai medical host platform can be compatible with all kinds of department mirrors, including products already on the market, products under research and iterative products; One machine with multiple mirrors can realize efficient connection.
In 2022, Ruipai medical products will cover more than 1000 hospitals, and the market share in key regions will exceed 50%. Among them, Ruipai Medical has hosted several national series of academic forums in many provinces and cities with the theme of "There is something new outside, Jingrui Forum", with a total of nearly 2000 participants. At the same time, Ruipai Medical, together with experts, held a hands-on training course in primary hospitals to help improve the diagnosis and treatment level of primary hospitals and help local people get through the last mile of medical treatment.
In 2022, Ruipai Medical successively participated in American Digestive Disease Week (DDW 2022), American Association of Urology (AUA 2022), European Association of Urology (EAU 2022), Arab Urology Annual Conference and Jordan Urology Annual Conference (AAU&JAUS 2022), the 11th International Urology Conference (EUSC) of the United Arab Emirates, etc. At present, Ruipai Medical has obtained 16 overseas registration certificates including CE, and its overseas sales channels cover more than 20 countries and regions in Europe, the Middle East, North America, South America, Southeast Asia, etc.
